🏛️ Verified NIH Record • Updated 2026-08-14

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) (NCT06858579)

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Dianthus Therapeutics

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (14 items) and avoid the listed exclusions (12 items).

Location: Clinical Study Site — Birmingham, Alabama

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Clinical signs or symptoms suggestive of polyneuropathy of causes other than CIDP.
  • Known evidence of central demyelination or known history of myelopathy.
  • History or presence of significant medical/surgical condition including any acute illness or major surgery considered to be clinically significant or that could have a potential impact on safety/efficacy or study procedures.
  • Any other condition, including mental illness or prior therapy that would make the participant unsuitable for this study.
  • Known complement deficiency or history of positive titer for anti-C1 antibodies.
  • Diagnosis of systemic lupus erythematosus (SLE) or family history of SLE (defined as a parent, sibling, or child).
  • Participants with an autoimmune disease affecting joints, muscle or nervous system.
  • Any coexisting or overlapping condition, which may interfere with outcome assessments, such as severe diabetic neuropathy, fibromyalgia, inflammatory arthritis or osteoarthritis affecting the hands and feet.
  • Prior history of N. meningitidis infection.
  • History of active malignancy within 5 years prior to screening, except basal cell carcinoma of the skin, curatively resected squamous cell carcinoma of the skin, cervical carcinoma in situ curatively treated or low-grade prostate adenocarcinoma for which appropriate management is observation alone.
  • Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (188 Sites)

  • Clinical Study Site — Birmingham, Alabama
  • Clinical Study Site — Phoenix, Arizona
  • Clinical Study Site — Scottsdale, Arizona
  • Clinical Study Site — Los Angeles, California
  • Clinical Study Site — San Francisco, California
  • Clinical Study Site — San Francisco, California
  • Cinical Study Site — New Haven, Connecticut
  • Clinical Study Site — Washington D.C., District of Columbia
  • Clinical Study Site — Maitland, Florida
  • Clinical Study Site — Tampa, Florida
  • Clinical Study Site — Honolulu, Hawaii
  • Clinical Study Site — Chicago, Illinois
  • Clinical Study Site — Edwardsville, Illinois
  • Clinical Study Site — Indianapolis, Indiana
  • Clinical Study Site — Kansas City, Kansas
  • Clinical Study Site — Burlington, Massachusetts
  • Clinical Study Site — East Lansing, Michigan
  • Clinical Study Site — Omaha, Nebraska
  • Cinical Study Site — Lebanon, New Hampshire
  • Clinical Study Site — New York, New York
  • Clinical Study Site — New York, New York
  • Clinical Study Site — Cincinnati, Ohio
  • Clinical Study Site — Columbus, Ohio
  • Clinical Study Site — Portland, Oregon
  • Cinical Study Site — Nashville, Tennessee

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗